Guanfacine

Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) [1][2][3].

Product Specifications

CAS Number

[29110-47-2]

UNSPSC

12352005

Hazard Statement

H301, H311, H331

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/guanfacine.html

Concentration

10mM

Purity

99.85

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC(N)=N)CC1=C(Cl)C=CC=C1Cl

Molecular Formula

C9H9Cl2N3O

Molecular Weight

246.09

Precautions

H301, H311, H331

References & Citations

[1]Amy F T Arnsten, et al. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012 Mar;85 (1) :45-58. Epub 2012 Mar 29.|[2]P. A. Van Zwieten, et al. The pharmacology of centrally acting antihypertensive drugs. Br J Clin Pharmacol. 1983; 15 (Suppl 4) : 455S–462S. |[3]Min Wang, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007 Apr 20;129 (2) :397-410.